[1] Wang FS, Fan JG, Zhang Z, et al.The global burden ofliver disease:The major impact of China[J].Hepatology,2014,60(6):2099-2108. [2] Zhou F,Zhou JH,Wang W, et al.Unexpected rapid increase in the burden of NAFL DinChina from 2008 to 2018:A systematic review and meta‐analysis[J].Hepatoloqy,2019,70(4):1119-1133. [3] 卫霞. 血脂、血糖、肝功能和血尿酸联合检测在老年脂肪肝诊断中的应用研究[J].临床医学,2022,42(5):76-78. [4] Tokushige K, Lkejima K, Ono M, et al.Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalc oholic steatohepatitis 2020[J].J Gastroenterol,2021,56(11):951-963. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志,2018,34(5):947-957. [6] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等. 中国脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 中华肝脏病杂志,2019,27(10):748-753. [7] 诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)[J].中国循环杂志,2016,31(10):937-953. [8] BorghiC, Domienik‐KartowiczJ, Tykarski A, et al.Expert consensus for the diagnosis and treatment of patient with hyperur cemia and high cardiovascular risk:2021 update[J].Cardiol J,2021,28(1):1-14. [9] 范利,华琦,贾建军,等.老年高血压合并认知障碍诊疗中国专家共识(2021版)[J].中国心血管杂志,2021,26(2):101-111. [10] 中国医师协会内分泌代谢科医师分会,国家代谢性疾病临床医学研究中心.糖尿病分型诊断中国专家共识[J].中华糖尿病杂志,2022,14(2):120-139. [11] 王友发,孙明晓,杨月欣.《中国肥胖预防和控制蓝皮书》[M].北京:北京大学医学出版社,2019. [12] 范能光,彭亮,夏振华,等.正常血清尿酸与非酒精性脂肪性肝病的相关性研究[J].中国糖尿病杂志,2017,25(11):970-973. [13] Jain A.Pediatric fatty liverdisease[J].Mo Med,2019,116(2):123-128. [13] Paik JM, Kabbara K,Eberly KE, et al.Global burden of non‐alcoholic fatty liver disease (NAFLD) and chronic liver disease(CLD)among adolescents and young adults[J].Hepatology, 2022,75(5):1204-1217. [14] 林俊红,林常青,翁娜,等.中年女性高血压体检者体质指数异常与脂肪肝发病率的相关性研究及护理干预[J].全科护理,2020,18(10):1212-1214. [15] 段琼,张紫行,徐娟,等.高尿酸血症与脂肪肝关联的前瞻性队列研究[J].中华疾病控制杂志,2022,26(12):1420-1425,1432. [16] 章萌,张姗,金笑寒,等.体重指数与非酒精性脂肪肝关联的国内外研究现状[J].中国健康教育,2022,38(1):76-80. [17] Sugiyama A, Kurisu A, Ouoba S, et al.Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008-2019[J]. Liver Int,2021,41(12):2914-2923. [18] Naeini F, Namkhah Z, Tutunchi H, et al.Effects of naringenin supplementation on cardiovascular risk factors in overweight/obese patients with nonalcoholic fatty liver disease: A pilot double‐blind, placebo‐controlled, randomized clinical trial[J]. Eur J Gastroenterol Hepatol,2022,34(3):345-353. [19] 张文婷,刘丹,毛琛,等.加强儿童营养与健康研究推动儿童期肥胖防控[J].中华疾病控制杂志,2021,25(5):500-503. [20] Lee S, Kim KW, Lee J, et al.Visceral fat area is an independent risk factor for overweight or obese nonalcoholic fatty liver disease in potential living liver donors[J].Transplant Proc,2022,54(3):702-705. |